A New Era in the Treatment of Chronic HCV Infection08 June 2011
In May 2011, the FDA has approved two new drugs to treat chronic hepatitis C (HCV) infection. The two drugs, Boceprevir (Victrelis) from Merck & Co. and Telaprevir (Incivek) from Vertex (in collaboration with Tibotec), both act as inhibitors of HCV's protease enzyme. This is the first time in...
New Treatments Available Soon for HCV Infection03 May 2011
On April 27 and 28, the FDA's Antiviral Drugs Advisory Committee reviewed all available data presented to support approval of two new molecules developed separately by Merck & Co. (initially by Schering-Plough) and Vertex Pharmaceuticals for the treatment of chronic HCV infection. The two...
HIV can use ribonucleotides to replicate inside macrophages01 February 2011
In a paper published in Journal of Biological Chemistry (Dec. 10 issue), Kennedy et al. from University of Rochester Medical Center and Emory University reported evidence that HIV has developed an original strategy to replicate efficiently in non-dividing macrophages despite the absence of...
19th Conference on Retroviruses and Opportunistic Infections (CROI)
Washington State Convention Center, Seattle (WA), USA - March 5-8, 2012 http://www.retroconference.org/2012/
XIV International Symposium on Respiratory Viral Infections
Istanbul, Turkey - March 23-26, 2012 http://www.themacraegroup.com/2012-symposia
Journées Québécoises VIH
Hôtel Delta, Montréal, Québec, Canada; 15-16 Mars 2012 http://www.symposiumsida.ca